B+
Bull case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
ATEC
AlphatecBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The operating thesis improved after Q2: strong procedure and surgeon growth coincided with materially higher adjusted EBITDA and positive free cash flow. Secondary market-data pages list constructive post-print target actions, including UBS raising $15 to $16, TD Cowen raising $11 to $13, and BMO Capital raising $11 to $12 ([Benzinga](https://www.benzinga.com/quote/ATEC/price-targets)).
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.8.
What can break
ATEC continues to report GAAP net losses despite adjusted EBITDA profitability; Q2 GAAP net loss was $26 million [#SEC-8K-2026-08-04].
Momentum
24
Value
48
Sentiment
80
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.50 · Bull $16.00 · Bear $7.00Analysis 2026-09-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $15.79
Why
Momentum24 · Δ7d +3.6
Value48 · Δ7d -0.1
Sentiment80 · Δ7d +6.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.8.
Contradictions & invalidation
- • ATEC continues to report GAAP net losses despite adjusted EBITDA profitability; Q2 GAAP net loss was $26 million [#SEC-8K-2026-08-04].
- • Biologics attachment and revenue per case may remain below prior-year levels, limiting revenue quality and margin conversion [#PR-EARNINGS-2026-08-12].
- • The market has not fully rewarded the reported improvement, and secondary sources disagree on the immediate post-earnings reaction, with one reporting roughly a 7.5% next-day decline ([TipRanks](https://www.tipranks.com/stocks/atec/earnings)) and another describing a modest gain.
Catalyst clock
2026-09-30
Potential post-Q2 profitability rerating
Lead driver: Sentiment · See AI snapshot
Momentum
24
9% active weight
Current posture
7d trendImproving
Δ7d
+3.6
Δ21d
-14.3
Value
48
28% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+1.0
Sentiment
80
62% active weight
Current posture
7d trendImproving
Δ7d
+6.8
Δ21d
+8.2
Why this grade
Composite grade B. Momentum 23.8 / Value 48.1 / Sentiment 80.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-04. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$12.50
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.46B
Beta
1.02
Shares Out
154.45M
P/E (TTM) · Derived
-9.9
P/S (TTM)
4.33
P/FCF (TTM) · Derived
586.96
Rev YoY
+15.1%
EPS YoY
-40.0%
Gross Margin
+61.4%
Op Margin
-4.8%
Net Debt
$435.29M
Current Ratio
1.89
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data